Dr. Eric M. Lander, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Arizona College of Medicine (2018)
- Years since graduation
- 8
- In the NPI registry since
- 2018
- Medicare patients seen, 2024
- 89
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2018Medical school: University of Arizona College of Medicine
- 2018Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MN license 76468 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Abbott Northwestern Hospital Minneapolis, MN
- M Health Fairview Southdale Hospital Edina, MN
- M Health Fairview Ridges Hospital Burnsville, MN
- Ridgeview Medical Center Waconia, MN
Medical groups
- Minnesota Oncology Hematology PA (134 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 89
- Services billed
- 16,286
- Patients’ average age
- 73
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Enoxaparin Sodium Other prescribers in Minneapolis, MN | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $10,094 in total to this clinician.
| Stemline Therapeutics Inc. | $4,960 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $3,343 |
| Beone Medicines USA, Inc. | $1,650 |
| Intera Oncology, Inc | $142 |
| Consulting Fee | $9,953 |
|---|---|
| Food and Beverage | $142 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. May 12, 2025 | Consulting Fee | $3,343 |
| Stemline Therapeutics Inc. Oct 23, 2025 | Consulting Fee Orserdu · Oncology | $2,480 |
| Stemline Therapeutics Inc. Oct 23, 2025 | Consulting Fee Orserdu · Oncology | $2,480 |
| Beone Medicines USA, Inc. Dec 3, 2025 | Consulting Fee TEVIMBRA · Oncology | $1,650 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $50,358 in research payments for these studies, mostly to the institutions running them.
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Eli Lilly and Company · Active, not recruiting · NCT04188548 - A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
AbbVie Inc. · Recruiting · NCT07023289 - A phase iii, randomized, open-label, multicenter study evaluating the efficacy and safety of divaras
Genentech, Inc. - A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast C…
Merck Sharp & Dohme LLC - Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Mirati Therapeutics, Inc. · Active, not recruiting · NCT04793958 - Neoadjuvant NSCLC
Genentech, Inc. - A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in…
AstraZeneca Pharmaceuticals LP - A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy f…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.